Results 81 to 90 of about 11,011 (206)
Journal of Paediatrics and Child Health, Volume 62, Issue 5, Page 874-878, May 2026.
Sameena Tabassum +3 more
wiley +1 more source
Formoterol used as needed—clinical effectiveness
, 2001 A number of studies have already demonstrated the clinical effectiveness of formoterol when used as maintenance therapy in patients requiring both a β2-agonist with a long duration of action and a regular inhaled corticosteroid. However, formoterol has a
Selroos, O.
core +1 more source
Bronchodilation of formoterol administered with budesonide: Device and formulation effects
, 2008 BACKGROUND: Previous single-dose crossover studies have established therapeutic equivalence of formoterol when administered at the same nominal dose via a dry powder inhaler (DPI) or pressurized hydrofluoroalkane (HFA) metered-dose inhaler (pMDI ...
Mezzanotte, W., Miller, C., Senn, S.
core +1 more source
Patient Related Outcome Measures, 2011 Richard D O'ConnorSharp Rees-Stealy Medical Group, San Diego, CA, USAAbstract: In the United States, budesonide/formoterol pressurized metered-dose inhaler (pMDI) is approved for treatment of asthma in patients aged ≥12 years whose asthma ...
Richard D O'Connor
doaj
Budesonide and formoterol reduce early innate anti-viral immune responses in vitro
, 2011 Asthma is a chronic inflammatory airways disease in which respiratory viral infections frequently trigger exacerbations. Current treatment of asthma with combinations of inhaled corticosteroids and long acting beta2 agonists improves asthma control and ...
Kirkegard, Darren +25 more
core +1 more source
Inhibitory effect of formoterol on coronaviruses
, 2020 Formoterol is a long-acting β2 agonist (LABA) used as a bronchodilator in the management of asthma and COPD. The results of two studies suggest that inhaled formoterol might be used as additional therapeutic agent in the treatment of COVID-19, especially
Domina Petric
core +1 more source
International Journal of COPD, 2016 Marc Miravitlles,1 Kenneth R Chapman,2 Ferran Chuecos,3 Anna Ribera,4 Esther Garcia Gil3 1Department of Pneumology, Vall d’Hebron University Hospital, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; 2Asthma & Airway Centre ...
Miravitlles M +4 more
doaj
Acute formoterol administration has no ergogenic effect in nonasthmatic athletes
, 2002 Purpose: To determine the effect of formoterol (formoterol fumarate dihydrate) on the aerobic and anaerobic capacities of highly trained athletes.\ud \ud Methods: 10 male athletes (age = 26.2 +/- 0.9, O2max = 65.6 +/- 2.4 mL[middle dot]kg-1[middle dot ...
McKenzie, Donald C. +2 more
core
Formoterol in clinical practice—safety issues
, 2001 While short-acting β2-agonists are seen as the cornerstone of treatment as relief medication for asthma, current guidelines recommend long-acting β2-agonists as maintenance therapy in combination with inhaled corticosteroids in patients with moderate to ...
Rabe, K.F.
core +1 more source
, 2018 Inflammatory diseases are associated with muscle wasting as a result of an increase in proteolysis. The purpose of this study was to elucidate whether administration of a β2 adrenergic agonist, formoterol, was able to prevent the acute effects of sepsis ...
Gómez SanMiguel, Ana Belén +3 more
core +1 more source